Stratification of Cutaneous Squamous Cell Carcinomas According to Its Transcriptomic, Metabolic and Inflammatory Characteristics
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 200
- 试验地点
- 2
- 主要终点
- Percentages of individual immune cell populations among total tumor-infiltrating immune cells will be evaluated.
研究概览
简要总结
A collection of biological samples (skin) will be created to meet the objectives. Skin biopsies will be taken (excluding on face and fold), in accordance with standard practice.
详细描述
Skin cancers are the most common type of cancer in human. Among them, cutaneous squamous cell carcinomas (cSCCs) represent the 2nd most frequent, with an incidence that continues to grow (+300% between 1994 and 2006) in line with the ageing of the population and sun exposure habits. cSCCs is a multi-stage carcinogenesis model: the pre-cancerous lesion is actinic keratosis (AK), which can either regress or progressively evolve into cSCC in situ and then infiltrating, and in some patients into a metastatic stage, initially lymph node and then distant, life-threatening. cSCCs are classified as low-risk or high-risk according to clinical and histological criteria associated with the risk of recurrence and metastasis. However, there is currently no tool for predicting this risk for a given cSCC, particularly according to its genetic characteristics. Indeed, the high mutation rate makes it difficult to identify specific genetic profiles. Similarly, there is no tool to predict the potential for a precancerous lesion (AK) to regress or to develop into a cSCC. The aim of this study is to characterize the molecular and metabolic features as well as immunologic landscapes of precancerous AK and cSCCs in order to uncover epithelial and immune cell subpopulations supporting tumor progression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 18 or over,
- •Patients with suspected AK, or cSCC lesions (in situ, infiltrating or metastatic),
- •Patients able to sign a consent form,
- •Patients affiliated to a French Social Security system.
排除标准
- •Patients who have previously received systemic treatment (chemotherapy, immunotherapy),
- •Patients with cSCC or AK localized on visible zone of the face or folds
- •Patients under guardianship or guardianship,
- •Patient not affiliated to a French Social Security system.
结局指标
主要结局
Percentages of individual immune cell populations among total tumor-infiltrating immune cells will be evaluated.
时间窗: Day 1
Characterization of the immune cells infiltrate Expression of multiple immune cell markers will be assessed in samples from different subtypes of cSCC by single cell RNA sequencing.
Relative abundance of metabolite and differential enzyme expression in tumor lesion versus healthy tissue
时间窗: Day 1
Evaluation of metabolic changes involved in cSCC progression
次要结局
- percentage of samples in each category (AK, in situ, ...) that present differentiation features are assessed by immunostaining of loricrin, filaggrin, K10(Day 1)
- percentage of samples expressing aggressive markers will be assessed by evaluating the proliferation index(Day 1)
- percentage of samples that are highly proliferative will be calculated by measuring the ability of colony formation (SRB Test)(Day 1)
